Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 16
GLP-1 Drugs for Antipsychotic Weight Gain
A 2026 meta-analysis found GLP-1 drugs reduced antipsychotic-related weight and metabolic measures, with more gastrointestinal side effects.
GLP-1 Drugs and Bone Density Review
A 2026 review found GLP-1 bone evidence too sparse for a class verdict, while small semaglutide and liraglutide trials raised questions.
GLP-1 Facial Changes: What Data Show
A 2026 review links GLP-1-associated facial hollowing mainly to weight loss, while drug-specific effects and prevention remain uncertain.
Are GLP-1 Trials Measuring Nausea Well?
A 2026 review finds that major GLP-1 obesity trials recorded nausea without a validated, symptom-specific patient questionnaire.
No Trial Defines the KLOW Plus CJC Stack
No clinical trial defines dosing or timing for a KLOW, CJC-1295, and ipamorelin stack, and the component evidence cannot create a protocol.
Semaglutide and Adipose Inflammation
A 2026 mouse study found semaglutide briefly suppressed visceral-fat inflammation before weight regain reversed the tissue changes.
Tesamorelin or CJC/Ipamorelin?
Tesamorelin, CJC-1295, and ipamorelin affect the growth-hormone axis, but no head-to-head evidence supports switching or cycling among them.
BPC-157 Fusion Proteins: Rat Readout
A 2026 BPC-157 study tested two bacteria-made fusion proteins in a rat stomach-ulcer model, not ordinary BPC-157 in people.
Butyrate and Semaglutide in Obese Mice
Butyrate increased semaglutide's body-weight effect in obese mice, but the study provides no evidence of added efficacy in people.
CJC-1295 Dosing in Human Studies
Human CJC-1295 studies report dose levels for short hormone-response experiments, not an approved dose or a self-use protocol.
GLP-1 Cardiovascular Trials: 2026 Review
A 2026 review links five major cardiovascular, kidney and heart-failure trials, but each result belongs to a specific drug, population and endpoint.
Gut-Brain Axis in Alzheimer's
A 2026 review maps gut-immune pathways in Alzheimer's disease but reports no new patient outcomes and no proven microbiome treatment.